Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thyroid: Year-in-Review 2024-2025.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2025
Same author

Aberrant engagement of P-selectin drives hematopoietic stem cell aging in mice.

Nature aging·2025
Same author

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.

Nature cancer·2024
Same author

Regulation of the hematopoietic stem cell pool by C-Kit-associated trogocytosis.

Science (New York, N.Y.)·2024
Same author

An iron rheostat controls hematopoietic stem cell fate.

Cell stem cell·2024
Same author

TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells.

Nature communications·2024
Same journal

Psychological stress drives aging-like hematopoietic stem cell dysfunction through a brain-gut-bone marrow axis.

Cell stem cell·2026
Same journal

Human stem cell-based embryo model governance: Insights from Japan.

Cell stem cell·2026
Same journal

From reconstruction to intervention: Engineered organoids as living therapeutic depots.

Cell stem cell·2026
Same journal

Long-term lessons from MATCH01 macrophage therapy in cirrhosis.

Cell stem cell·2026
Same journal

Beyond apoptosis: LSC state dictates metabolic and anti-apoptotic vulnerabilities.

Cell stem cell·2026
Same journal

Outside the niche: Gut microbiota relay psychological stress to hematopoietic stem cell dysfunction.

Cell stem cell·2026
See all related articles

Related Experiment Video

Updated: Oct 1, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K

SEPHguarding acute myeloid leukemia.

Malini Gupta1, Britta Will2

  • 1Department of Cell Biology, Albert Einstein College of Medicine, NY, USA.

Cell Stem Cell
|March 4, 2022
PubMed
Summary
This summary is machine-generated.

Aberrant gene regulation drives acute myeloid leukemia (AML) growth and resistance. Researchers found that targeting selenophosphate synthetase 2 (SEPHS2) overexpression, driven by oncogenic enhancers, offers a new strategy against AML.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.7K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.4K

Related Experiment Videos

Last Updated: Oct 1, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.7K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Aberrant gene regulation is a key characteristic of malignant growth in acute myeloid leukemia (AML).
  • Therapy resistance in AML is often linked to adaptive changes in gene expression.
  • Understanding the molecular drivers of AML is crucial for developing effective treatments.

Purpose of the Study:

  • To identify specific molecular targets for mitigating malignant cell growth in AML.
  • To investigate the role of oncogenic enhancers in driving gene overexpression in AML.
  • To explore the therapeutic potential of targeting selenophosphate synthetase 2 (SEPHS2) in AML.

Main Methods:

  • Gene expression analysis to identify aberrant regulatory patterns.
  • Chromatin immunoprecipitation (ChIP) to map enhancer activity.
  • Functional assays to assess the impact of SEPHS2 modulation on AML cell growth.

Main Results:

  • Identified oncogenic enhancer-driven overexpression of SEPHS2 in AML.
  • Demonstrated that SEPHS2 plays a critical role in promoting malignant cell proliferation.
  • Showcased SEPHS2 as a potential therapeutic target for AML.

Conclusions:

  • Targeting SEPHS2 offers a promising strategy for AML therapy.
  • Understanding enhancer-driven gene regulation provides new avenues for cancer treatment.
  • This study highlights SEPHS2 as a vulnerability in AML that can be exploited therapeutically.